Nkarta Inc (NKTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nkarta Inc (NKTX) has a cash flow conversion efficiency ratio of -0.098x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.22 Million) by net assets ($247.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NKTX company net worth for the company's overall valuation and market capitalisation.
Nkarta Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Nkarta Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nkarta Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nkarta Inc ranked by their cash flow conversion efficiency. See NKTX operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quang Viet Enterprise Co Ltd
TW:4438
|
-0.156x |
|
Skue Sparebank
OL:SKUE
|
0.056x |
|
SEACOR Marine Holdings Inc
NYSE:SMHI
|
-0.061x |
|
Tah Hsin Industrial Corp
TW:1315
|
0.013x |
|
Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
|
-0.116x |
|
Octave Specialty Group, Inc.
NYSE:OSG
|
-0.006x |
|
Jakarta Setiabudi Internasional
JK:JSPT
|
0.044x |
|
Angel Oak Mortgage Inc
NYSE:AOMR
|
0.026x |
Annual Cash Flow Conversion Efficiency for Nkarta Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Nkarta Inc from 2018 to 2025. View latest Nkarta Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $312.32 Million | $-88.70 Million | -0.284x | -16.22% |
| 2024-12-31 | $407.98 Million | $-99.70 Million | -0.244x | +22.49% |
| 2023-12-31 | $273.29 Million | $-86.16 Million | -0.315x | -105.87% |
| 2022-12-31 | $372.21 Million | $-57.00 Million | -0.153x | +43.42% |
| 2021-12-31 | $250.97 Million | $-67.93 Million | -0.271x | -99.84% |
| 2020-12-31 | $321.22 Million | $-43.51 Million | -0.135x | -118.79% |
| 2019-12-31 | $-25.48 Million | $-18.37 Million | 0.721x | -24.97% |
| 2018-12-31 | $-5.40 Million | $-5.18 Million | 0.961x | -- |
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myo… Read more